Clinical Trial Update: Daptomycin as Adjunctive Therapy for Staphylococcus Aureus Bacteremia [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating daptomycin as adjunctive therapy for methicillin-susceptible Staphylococcus aureus bacteremia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Methicillin-susceptible Staphylococcus Aureus Septicemia
• Staphylococcus Aureus Bacteremia

Drugs mentioned

• Daptomycin (daptomycin)

Snippet

Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre | Conditions: Methicillin Susceptible Staphylococcus Aureus Septicemia, Bacteremia | Phase 4 | Status: COMPLETED